Rachel Reed, PA
Physician Assistant · Morehead City, NCNPI 1417145293
Payments from drug & device makers
Across 125 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$262
- GSK$240
- Pfizer$237
- Lilly USA, LLC$206
- Amgen$167
- Novo Nordisk$145
- plus $778 from 18 others
What the payments were for
- Food & beverage$2,036100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $262 |
| GSK | 15 | $240 |
| Pfizer | 13 | $237 |
| Lilly USA, LLC | 15 | $206 |
| Amgen | 12 | $167 |
| Novo Nordisk | 7 | $145 |
| AbbVie | 7 | $123 |
| Merck | 7 | $108 |
| Lundbeck LLC | 3 | $70 |
| Abbott | 3 | $63 |
| Boehringer Ingelheim | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Almatica Pharma LLC | 3 | $42 |
| Boston Scientific | 2 | $40 |
| Astellas Pharma US Inc | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Intra-sana Laboratories | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$2,036 in reported general payments places this provider in the 80th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $83,893 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $59,147 |
| EliquisApixaban | 26 | $42,329 |
| JardianceEmpagliflozin | 29 | $41,689 |
| FarxigaDapagliflozin Propanediol | 37 | $26,580 |
| XareltoRivaroxaban | 21 | $24,237 |
| MounjaroTirzepatide | 17 | $17,993 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,373 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,205 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 34 | $7,450 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $7,320 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 64 | $4,314 |
| Atorvastatin Calcium | 278 | $3,182 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 33 | $2,312 |
| Valsartan | 57 | $2,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $145 | $83,89369 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $240 | $76,969101 claims |
| PfizerEliquis | $237 | $42,32926 claims |
| Boehringer IngelheimJardiance | $62 | $41,68929 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $262 | $36,78554 claims |
| Lilly USA, LLCMounjaro | $206 | $17,99317 claims |
| AbbVieSynthroid | $123 | $1,17615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Morehead City
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
- Jay ClarkeArden$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.